CVS stops sale of heartburn drugs with suspect contaminant
CVS has halted sales of popular heartburn treatment Zantac and the store generic version after warnings by U.S. health regulators.
CVS is the latest retailer to pull the heartburn tablets from store shelves. Earlier this month, the U.S. Food and Drug Administration warned consumers about a potentially dangerous contaminant in prescription and over-the-counter versions of Zantac. The agency said it had detected a “probable” cancer-causing chemical in the medications, which are sold as both prescription and over-the-counter treatments to treat stomach acid and ulcers.
In its announcement this weekend, CVS said customers who bought Zantac products could return them for a refund. The retailer will continue to sell other heartburn medications, such as Pepcid.
Some manufacturers of the drug have stopped distribution. Health officials say concerned patients should consult their doctor.
Your guide to our new economic reality.
Get our free business newsletter for insights and tips for getting by.
You may occasionally receive promotional content from the Los Angeles Times.
More From the Los Angeles Times
-
Movie star Sylvester Stallone is aiming for a blockbuster sale in Beverly Park, listing his 21,000-square-foot mansion for $110 million.
-
Stocks swerved to a mixed finish on Wall Street on Monday, ahead of a deluge of corporate earnings reports scheduled to arrive this week.
-
A head-scratching David and Goliath story is playing out on Wall Street over the stock price of a money-losing videogame retailer
-
Marc Rowan, one of Leon Black’s top lieutenants, is to succeed him as CEO of private equity giant Apollo Global Management. Black will stay on as chairman.
